Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
Am J Physiol Renal Physiol ; 304(3): F300-7, 2013 Feb 01.
Article in English | MEDLINE | ID: mdl-23171555

ABSTRACT

There is a lack of suitable animal models that replicate the slowly progressive chronic interstitial fibrosis that is characteristic of many human chronic nephropathies. We describe a chronic long-term (6-mo) model of lithium-induced renal fibrosis, with minimal active inflammation, which mimics chronic kidney interstitial fibrosis seen in the human kidney. Rats received lithium via their chow (60 mmol lithium/kg food) daily for 6 mo. No animals died during the exposure. Nephrogenic diabetes insipidus was established by 3 wk and persisted for the 6 mo. Following metabolic studies, the animals were killed at 1, 3, and 6 mo and the kidneys were processed for histological and immunohistochemical studies. Progressive interstitial fibrosis, characterized by increasing numbers of myofibroblasts, enhanced transforming growth factor-ß(1) expression and interstitial collagen deposition, and a minimal inflammatory cellular response was evident. Elucidation of the underlying mechanisms of injury in this model will provide a greater understanding of chronic interstitial fibrosis and allow the development of intervention strategies to prevent injury.


Subject(s)
Kidney/drug effects , Kidney/pathology , Lithium/adverse effects , Lithium/pharmacology , Nephritis, Interstitial/chemically induced , Animals , Chronic Disease , Collagen/metabolism , Disease Models, Animal , Dose-Response Relationship, Drug , Fibrosis , Kidney/metabolism , Male , Nephritis, Interstitial/metabolism , Nephritis, Interstitial/pathology , Rats , Rats, Wistar , Time Factors , Transforming Growth Factor beta1/metabolism
2.
Nephrology (Carlton) ; 17(2): 182-8, 2012 Feb.
Article in English | MEDLINE | ID: mdl-21883672

ABSTRACT

AIM: Due to altered red blood cell survival and erythropoietin therapy glycated haemoglobin (HbA1c) may not accurately reflect long-term glycaemic control in patients with diabetes and chronic kidney disease (CKD). Glycated albumin (GA) and fructosamine are alternative markers of glycaemia. The aim of this study was to investigate the accuracy of HbA1c, GA and fructosamine as indicators of glycaemic control using continuous glucose monitoring. METHODS: HbA1c, GA and fructosamine concentrations were measured in 25 subjects with diabetic nephropathy (CKD stages 4 and 5 (estimated glomerular filtration rate <30 mL/min per 1.73 m(2) )) matched with 25 subjects with diabetes and no evidence of nephropathy. Simultaneous real-time glucose concentrations were monitored by continuous glucose monitoring over 48 h. RESULTS: GA correlated significantly to mean glucose concentrations in patients with and without CKD (r = 0.54 vs 0.49, P < 0.05). A similar relationship was observed with fructosamine relative to glucose. A poor correlation between HbA1c and glucose was observed with CKD (r = 0.38, P = ns) but was significant in the non-CKD group (r = 0.66, P < 0.001). The GA/HbA1c ratio was significantly higher in diabetic patients with CKD compared with controls (2.5 ± 0.4 vs 2.2 ± 0.4, P < 0.05). HbA1c values were significantly lower in CKD patients, relative to non-CKD patients at comparable mean glucose concentrations. CONCLUSION: HbA1c significantly underestimates glycaemic control in patients with diabetes and CKD stages 4 and 5. In severe CKD, GA more accurately reflects glycaemic control compared with fructosamine and HbA1c and should be the preferred marker of glycaemic control.


Subject(s)
Blood Glucose/drug effects , Diabetes Mellitus, Type 1/blood , Diabetes Mellitus, Type 2/blood , Diabetic Nephropathies/blood , Fructosamine/blood , Glycated Hemoglobin/metabolism , Monitoring, Physiologic , Serum Albumin/metabolism , Adult , Aged , Biomarkers/blood , Blood Glucose/metabolism , Case-Control Studies , Chronic Disease , Diabetes Mellitus, Type 1/complications , Diabetes Mellitus, Type 1/drug therapy , Diabetes Mellitus, Type 2/complications , Diabetes Mellitus, Type 2/drug therapy , Diabetic Nephropathies/etiology , Diabetic Nephropathies/therapy , Female , Glycation End Products, Advanced , Humans , Hypoglycemic Agents/therapeutic use , Male , Middle Aged , New Zealand , Peritoneal Dialysis , Regression Analysis , Renal Dialysis , Severity of Illness Index , Time Factors , Treatment Outcome , Glycated Serum Albumin
3.
J Pharmacokinet Pharmacodyn ; 38(6): 787-801, 2011 Dec.
Article in English | MEDLINE | ID: mdl-21997468

ABSTRACT

Anaemia of chronic kidney disease (CKD) is a common complication in patients with renal impairment, especially in end-stage renal failure. As well as erythropoietin deficiency, decreased red blood cell survival is a contributing factor. However, it remains unclear which mechanism underlies the altered survival of red blood cells (RBCs). In this work a previously developed statistical model for RBC survival was applied to clinical data obtained from 14 patients with CKD undergoing hemodialysis as well as 14 healthy controls using radioactive chromium (5¹Cr) as random labelling method. A classical two-stage approach and a full population analysis were applied to estimate the key parameters controlling random destruction and senescence in the model. Estimating random destruction was preferred over estimating an accelerated senescence in both approaches and both groups as it provided the better fit to the data. Due to significant nonspecific random loss of the label from the cells that cannot be quantified directly only a relative RBC survival can be obtained from data using 5¹Cr as labelling method. Nevertheless, RBC survival was found to be significantly reduced in CKD patients compared to the controls with a relative reduction of 20-30% depending on the analysis method used.


Subject(s)
Anemia/physiopathology , Cell Survival/physiology , Erythrocytes/physiology , Kidney Failure, Chronic/physiopathology , Models, Biological , Anemia/blood , Anemia/complications , Anemia/diagnostic imaging , Case-Control Studies , Chromium Radioisotopes , Erythrocytes/diagnostic imaging , Female , Humans , Kidney Failure, Chronic/blood , Kidney Failure, Chronic/complications , Kidney Failure, Chronic/diagnostic imaging , Male , Middle Aged , Radionuclide Imaging , Renal Dialysis
4.
Am J Kidney Dis ; 58(4): 591-8, 2011 Oct.
Article in English | MEDLINE | ID: mdl-21715072

ABSTRACT

BACKGROUND: Shortening of red blood cell (RBC) survival contributes to the anemia of chronic kidney disease. The toxic uremic environment accounts for the decreased RBC life span. The contribution of mechanical damage caused by hemodialysis to the shortened life span is unclear. Reductions up to 70% in RBC survival have been reported in uremic patients. To date, no accurate well-controlled RBC survival data exist in dialysis patients treated using different dialysis modalities and receiving erythropoiesis-stimulating agent (ESA) therapy. The aim of this study was to determine RBC survival in hemodialysis (HD) and peritoneal dialysis (PD) patients compared with healthy persons. STUDY DESIGN: Observational study. SETTING & PARTICIPANTS: 14 HD patients and 5 PD patients were recruited from the dialysis unit. Healthy volunteers (n = 14) age- and sex-matched to HD participants were included. All dialysis patients received either ESA therapy or regular iron supplementation. PREDICTOR: Dialysis patients versus age- and sex-matched healthy controls. OUTCOMES: RBC survival. MEASUREMENTS: RBC survival was determined using radioactive chromium labeling. RESULTS: More than 85% of dialysis patients were anemic (hemoglobin, 12.0 ± 1.1 g/dL); hemoglobin concentrations were not significantly different between HD and PD patients. Median RBC survival was significantly decreased by 20% in HD patients compared with healthy controls: 58.1 (25th-75th percentile, 54.6-71.2) versus 72.9 (25th-75th percentile, 63.4-87.8) days (P = 0.02). No difference was shown between the PD and HD groups: 55.3 (25th-75th percentile, 49.0-60.2) versus 58.1 (25th-75th percentile, 54.6-71.2) days (P = 0.2). LIMITATIONS: Label loss from RBCs associated with the chromium 51 labeling technique needs to be accounted for in the interpretation of RBC survival data. CONCLUSIONS: Despite current ESA therapy, decreased RBC survival contributes to chronic kidney disease-related anemia, although the reduction is less than previously reported. There does not appear to be net mechanical damage associated with HD therapy resulting in decreased RBC life span.


Subject(s)
Erythrocyte Aging , Kidney Failure, Chronic/blood , Renal Dialysis , Adult , Aged , Anemia/blood , Anemia/drug therapy , Anemia/epidemiology , Arteriolosclerosis/blood , Arteriolosclerosis/complications , Case-Control Studies , Chromium Radioisotopes/blood , Female , Hematinics/therapeutic use , Hemoglobins/analysis , Humans , Kidney Failure, Chronic/etiology , Kidney Failure, Chronic/therapy , Male , Middle Aged , New Zealand , Peritoneal Dialysis , Polycystic Kidney Diseases/blood , Polycystic Kidney Diseases/complications
5.
NDT Plus ; 4(6): 368-75, 2011 Dec.
Article in English | MEDLINE | ID: mdl-25984197

ABSTRACT

Diabetic nephropathy is the most common aetiology of end-stage kidney disease (ESKD). Strict glycaemic control reduces the development and progression of diabetes-related complications, and there is evidence that improved metabolic control improves outcomes in diabetic subjects with advanced chronic kidney disease (CKD). Glycaemic control in people with kidney disease is complex. Changes in glucose and insulin homeostasis may occur as a consequence of loss of kidney function and dialysis. The reliability of measures of long-term glycaemic control is affected by CKD and the accuracy of glycated haemoglobin (HbA1c) in the setting of CKD and ESKD is questioned. Despite the altered character of diabetes in CKD, current guidelines for diabetes management are not specifically adjusted to this patient group. The validity of indicators of longer term glycaemic control has been the focus of increased recent research. This review discusses the current understanding of commonly used indicators of metabolic control (HbA1c, fructosamine, glycated albumin) in the setting of advanced CKD (Stages 4 and 5, glomerular filtration rate <30 mL/min/1.73m(2)).

6.
Nephrology (Carlton) ; 16(1): 68-75, 2011 Jan.
Article in English | MEDLINE | ID: mdl-21175981

ABSTRACT

AIM: A pilot study to investigate the anti-inflammatory effect of insulin in patients on maintenance haemodialysis. BACKGROUND: Elevated concentrations of pro-inflammatory and oxidative mediators are thought to contribute to the increased cardiovascular risk in haemodialysis. Insulin has been demonstrated to have anti-inflammatory properties and a continuous low-dose insulin infusion in critically ill patients is associated with improved outcomes. The anti-inflammatory effects of insulin in haemodialysis have not been investigated. METHODS: In a single-blind cross-over study, 11 stable, non-diabetic, haemodialysis patients received a continuous insulin infusion (Actrapid 2 IU/h) during a dialysis of 4 h or a conventional dialysis in random order. Normoglycaemia was maintained by a modified glucose dialysate and glucose infusion. Blood samples were collected at baseline, 1, 4, 6 and 24 h. C-reactive protein (CRP), tumour necrosis factor-α, interleukin-6, neopterin, vascular cell adhesion molecule 1, protein thiols, dityrosine and peroxides were measured. RESULTS: Insulin produced a significant reduction in median CRP over the immediate dialysis phase (confidence interval) by 6% (2-9% (95% CI), P=0.006) and an even greater decline at 24 h (19% (8-28%, 95% CI), P=0.001) compared with values of the conventional dialysis. No significant changes were observed in the other markers. Median glucose levels were comparable during both dialysis sessions. CONCLUSIONS: During haemodialysis, insulin may have a modest anti-inflammatory effect as evident by a reduction in CRP that appears to have a persistent effect over the next 24 h post dialysis. More studies are required to examine longer-term benefits as well as the potential role in more high-risk individuals.


Subject(s)
Anti-Inflammatory Agents/therapeutic use , Inflammation/drug therapy , Insulin/therapeutic use , Renal Dialysis/adverse effects , Adult , Aged , C-Reactive Protein/metabolism , Cross-Over Studies , Female , Humans , Inflammation/etiology , Insulin/administration & dosage , Interleukin-6/blood , Male , Middle Aged , Neopterin/blood , New Zealand , Peroxides/blood , Pilot Projects , Single-Blind Method , Sulfhydryl Compounds/blood , Tumor Necrosis Factor-alpha/blood , Tyrosine/analogs & derivatives , Tyrosine/blood , Vascular Cell Adhesion Molecule-1/blood
7.
Eur Heart J ; 26(9): 914-20, 2005 May.
Article in English | MEDLINE | ID: mdl-15681576

ABSTRACT

AIMS: In women with Marfan syndrome pregnancy presents an increased risk of dilatation, dissection, and rupture of the aorta. The aim of this study was to investigate the influence of pregnancy on growth of the aortic root. METHODS AND RESULTS: Between 1993 and 2004 127 women with Marfan syndrome were prospectively followed; 61 women had one or more children; in 23 women, 33 pregnancies could be followed prospectively for aortic dimensions. Only one woman had suffered an aortic complication, a type A dissection (limited to the ascending aorta), before pregnancy. Out of 66 childless women a comparison group of 22 women was selected and individually matched. Mean initial aortic root diameter just before pregnancy was 37+/-5 mm (range 25-45). Before, during, and after pregnancy the overall individual aortic root diameter change (in 31 pregnancies) was not significant (P=0.77). Only the woman with a previous type A dissection developed an aortic complication (type B dissection) during her second pregnancy. No cardiac complications occurred in the other 22 women during their pregnancies. During a median follow-up of 6.4 years, no significant difference in growth of the aortic root was observed between the pregnancy group and the matched childless group (0.28 vs. 0.19 mm/year, P=0.08, respectively). CONCLUSION: Pregnancy in women with Marfan syndrome seems to be relatively safe up to an aortic root diameter of 45 mm, at least as far as our observed diameter range of 25-45 mm is concerned.


Subject(s)
Aortic Valve/pathology , Heart Valve Diseases/pathology , Marfan Syndrome/pathology , Pregnancy Complications, Cardiovascular/pathology , Adolescent , Adult , Aortic Valve/diagnostic imaging , Echocardiography , Female , Follow-Up Studies , Heart Valve Diseases/diagnostic imaging , Humans , Marfan Syndrome/diagnostic imaging , Pregnancy , Pregnancy Complications, Cardiovascular/diagnostic imaging , Prospective Studies
SELECTION OF CITATIONS
SEARCH DETAIL
...